Traders should now look for long-biased trades in AEZS as long as it's trending above today's low of $1.90, and then once it sustains a move or close above those breakout levels with volume that hits near or above 5700,360 shares. If that breakout triggers soon, then AEZS will set up to re-fill some of its previous gap down zone from October that started above $3. Any high-volume move above its 50-day at $2.98 will then put $3.55 to $4 into focus for AEZS.
This is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging diagnose. This stock is trading up 9.9% to $8.52 in recent trading.
Today's Range: $7.75-$8.5152-Week Range: $3.02-$11.11 Volume: 242,000 Three-Month Average Volume: 226,471 Shares of ECYT are soaring today after Summer Street started coverage on the stock with a buy rating and an $18 price target. From a technical perspective, ECYT is exploding higher here right near its 200-day moving average of $7.39 with above-average volume. This move has also pushed ECYT into breakout territory, since the stock has moved above some near-term overhead resistance at $8.24. This move is coming after ECYT recently downtrended from a high of $10.97 to its recent low of $7.50. Traders should now look for long-biased trades in ECYT as long as it's trending above its 200-day at $7.39, and then once it sustains a move or close above $8.24 with volume that hits near or above 226,471 shares. If ECYT can maintain that trend, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $9.50 to $10. Any high-volume move above those levels will then put $10.68 to $10.97 into focus for ECYT. Dynavax Technologies (DVAX) This is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases. This stock is trading up 8.7% to $2.90 in recent trading.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV